Jeil Pharmaceutical Co Ltd (271980) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Jeil Pharmaceutical Co Ltd stock KRW 10,583, price KRW 8,630, upside +22.6%, quality 52 out of 100. Rating: undervalued. Calculated from audited financials with 15 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range 8,550 KRW – 45,765 KRW · fair‑value band 9,406 KRW – 13,514 KRW · the 8,630 KRW price screens below the 10,583 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 9, 2026.
Follow Jeil Pharmaceutical Co in your weekly email
Every Wednesday you see whether Jeil Pharmaceutical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Jeil Pharmaceutical Co.,Ltd develops and supplies pharmaceutical products primarily in South Korea and internationally. It provides products in the areas of antibiotic, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamine.
Show moreShow less
The company exports its products. Jeil Pharmaceutical Co.,Ltd was founded in 1959 and is headquartered in Seoul, South Korea.
Stock analysis
Jeil Pharmaceutical Co Ltd (271980) currently trades at 8,630 KRW, while our model-based Fair Value estimate is 10,583 KRW, implying the stock looks roughly 18% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 26,423 KRW per share, and 12 of the 15 models we run sit above the 8,630 KRW price.
Bear case: the Asset-Based group reads lowest at 4,467 KRW, and 3 of the 15 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 9,406 KRW (bear) to 13,514 KRW (bull), the price of 8,630 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Jeil Pharmaceutical Co Ltd reported revenue of 567B KRW in FY2025 versus 701B KRW in FY2021, a compound −5.1%/yr. Reported net income was 23.4B KRW in FY2025.
Key figures
Market cap 126B KRW (≈ $93.0M) Micro · P/E ratio 13.6 · P/S ratio 0.23 · EPS (TTM) 633.60 KRW · Dividend yield 0.6% · Net margin 1.7% · Return on equity 9.1% · Return on assets (EBIT) −0.6% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 50% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 23%, 271980 screens cheaper than that median.
Fair Value models
Bear9,406 KRWFair Value 10,583 KRWBull13,514 KRW
Price 8,630 KRW · Upside +22.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (543.33 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.14/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−19.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.9%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.4%
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+28.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+27.7%
Dividend (yield on the price)0.6%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.2% → 4%
Compare Jeil Pharmaceutical Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 551 stocks
Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score52 · Below median
Fair Value upside+22.6% · Above median
Profitability
Return on equity (12 months)9.1% · Above median
Return on assets4.6% · Above median
Net margin (12 months)1.7% · Below median
Operating margin (12 months)−4.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)6.5% · Above median
Dividend yield (12 months)0.6% · Bottom 25%
Balance sheet
Debt / equity0.01× · Lowest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Jeil Pharmaceutical Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/271980
Frequently asked questions
Is Jeil Pharmaceutical Co Ltd (271980) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 10,583 KRW versus a price of 8,630 KRW, about +23% upside (undervalued).
What is the fair value of 271980?
Our model-based fair value for Jeil Pharmaceutical Co Ltd is 10,583 KRW (as of Nov 9, 2026), built from audited fundamentals. The current price: 8,630 KRW.
What is the quality score of 271980?
Jeil Pharmaceutical Co Ltd has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jeil Pharmaceutical Co Ltd (271980)?
Our model-based price target is the fair value of 10,583 KRW (as of Nov 9, 2026) from 15 valuation models. Cautious scenario 9,406 KRW, optimistic scenario 13,514 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Jeil Pharmaceutical Co Ltd stock forecast for 2026?
Our models put fair value at 10,583 KRW, about +23% upside versus a price of 8,630 KRW (undervalued). Cautious scenario 9,406 KRW, optimistic scenario 13,514 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Jeil Pharmaceutical Co Ltd (271980)?
Jeil Pharmaceutical Co Ltd reported trailing-twelve-month revenue of about 543B KRW (latest available figure, as of Nov 9, 2026).
Does Jeil Pharmaceutical Co Ltd pay a dividend?
Jeil Pharmaceutical Co Ltd currently shows a dividend yield of 0.56% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of Jeil Pharmaceutical Co Ltd (271980)?
Jeil Pharmaceutical Co Ltd has a dividend yield of 0.6%.
What is the intrinsic value of Jeil Pharmaceutical Co Ltd (271980)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jeil Pharmaceutical Co Ltd it is 10,583 KRW per share (as of Nov 9, 2026), against a price of 8,630 KRW. It is the blended result of 15 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Jeil Pharmaceutical Co Ltd stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 271980 trades below its calculated fair value: price 8,630 KRW, fair value 10,583 KRW, a gap of about +23% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 271980?
No. The price is what the market pays today (8,630 KRW); the fair value is what the company's own numbers justify (10,583 KRW). For Jeil Pharmaceutical Co Ltd the two are 1,953 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Jeil Pharmaceutical Co Ltd worth?
The market values Jeil Pharmaceutical Co Ltd at about 126B KRW (market capitalisation, as of Nov 9, 2026). Per share that is 8,630 KRW; our models calculate a fair value of 10,583 KRW per share.
What do the bullish and bearish scenarios say about 271980?
Our models span a range for Jeil Pharmaceutical Co Ltd: cautious scenario 9,406 KRW, base 10,583 KRW, optimistic 13,514 KRW per share (as of Nov 9, 2026, price 8,630 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 271980?
Jeil Pharmaceutical Co Ltd trades at a price-to-earnings ratio of 13.6 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 10,583 KRW is built from several models across several years. Other multiples: P/B 0.6, P/S 0.2, EV/EBITDA 4.6.
How solid is the balance sheet of Jeil Pharmaceutical Co Ltd (271980)?
Balance-sheet figures for Jeil Pharmaceutical Co Ltd (as of Nov 9, 2026): return on equity 9.1%, debt of 0.01 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is 271980 from its 52-week high?
Jeil Pharmaceutical Co Ltd trades at 8,630 KRW, about 50% below its 52-week high of 17,390 KRW and 1% above the low of 8,550 KRW (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 10,583 KRW is for.
Which stocks are comparable to Jeil Pharmaceutical Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jeil Pharmaceutical Co Ltd stock attractive at the current price?
The data as of Nov 9, 2026: price 8,630 KRW, calculated fair value 10,583 KRW (+23%), Quality Score 52/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 271980 calculated?
We run Jeil Pharmaceutical Co Ltd through 15 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 10,583 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Jeil Pharmaceutical Co Ltd currently trades 18% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Jeil Pharmaceutical Co Ltd (271980)?
The closing price on Nov 9, 2026 was 8,630 KRW. Our model-based fair value is 10,583 KRW, about +23% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Jeil Pharmaceutical Co Ltd right now?
The price is below even our cautious bear case (9,406 KRW). The market is more pessimistic than our downside scenario. Solid quality (52/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Jeil Pharmaceutical Co Ltd
How large is the market capitalisation of Jeil Pharmaceutical Co Ltd (271980)?
The market capitalisation of Jeil Pharmaceutical Co Ltd is 126B KRW (≈ $93.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jeil Pharmaceutical Co Ltd (271980)?
The price-to-sales ratio of Jeil Pharmaceutical Co Ltd is 0.23 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Jeil Pharmaceutical Co Ltd (271980)?
Earnings per share at Jeil Pharmaceutical Co Ltd are 633.60 KRW (price ÷ EPS = P/E 13.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Jeil Pharmaceutical Co Ltd (271980)?
The dividend yield of Jeil Pharmaceutical Co Ltd is 0.6% (payout 7.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Jeil Pharmaceutical Co Ltd (271980)?
The net margin of Jeil Pharmaceutical Co Ltd is 1.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Jeil Pharmaceutical Co Ltd (271980)?
The return on equity (ROE) of Jeil Pharmaceutical Co Ltd is 9.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jeil Pharmaceutical Co Ltd (271980)?
On an EBIT basis the return on assets of Jeil Pharmaceutical Co Ltd is −0.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jeil Pharmaceutical Co Ltd (271980)?
The operating margin of Jeil Pharmaceutical Co Ltd is −4.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Jeil Pharmaceutical Co Ltd (271980)?
Revenue at Jeil Pharmaceutical Co Ltd is growing +6.5% versus a year earlier (3y avg −7.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Jeil Pharmaceutical Co Ltd (271980)?
Earnings per share at Jeil Pharmaceutical Co Ltd are growing +103% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Jeil Pharmaceutical Co Ltd (271980) generate?
The free cash flow of Jeil Pharmaceutical Co Ltd is −14.8B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Jeil Pharmaceutical Co Ltd (271980) carry?
The net debt of Jeil Pharmaceutical Co Ltd is 41.6B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Jeil Pharmaceutical Co Ltd in the live analysis
One click puts Jeil Pharmaceutical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 9, 2026